Efficacy and safety of alternate day therapy with atorvastatin and fenofibrate combination in mixed dyslipidemia: A randomized controlled trial

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 19, Issue 3, 2014, Pages 296-303

  Harivenkatesh, Natarajan ^a   David, Darling Chellathai ^b   Haribalaji, Natarajan ^c   Sudhakar, Muthiah Kothandaramanujam ^b  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b SRI RAMACHANDRA UNIVERSITY   (India)

^c Rathimed Speciality Hospital   (India)

Author keywords

alternate day therapy; atorvastatin; cost effectiveness; fenofibrate; fixed dose combination; mixed dyslipidemia

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN PLUS FENOFIBRATE; CREATININE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PARACETAMOL; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; ATORVASTATIN; CHOLESTEROL; DRUG COMBINATION; FENOFIBRATE; HEPTANOIC ACID DERIVATIVE; PYRROLE DERIVATIVE;

ADULT; ARTHRALGIA; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; COST; COST CONTROL; COST EFFECTIVENESS ANALYSIS; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG THERAPY; DRUG TOLERABILITY; DYSLIPIDEMIA; FEMALE; FOLLOW UP; GASTRITIS; HUMAN; MAJOR CLINICAL STUDY; MALE; MIXED DYSLIPIDEMIA; MYALGIA; OPEN STUDY; PILOT STUDY; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; COST BENEFIT ANALYSIS; DRUG ADMINISTRATION; DRUG COMBINATION; DYSLIPIDEMIAS; ECONOMICS; MIDDLE AGED;

ADULT; CHOLESTEROL; COST-BENEFIT ANALYSIS; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; DYSLIPIDEMIAS; FEMALE; FENOFIBRATE; HEPTANOIC ACIDS; HUMANS; HYPOLIPIDEMIC AGENTS; MALE; MIDDLE AGED; PYRROLES; TRIGLYCERIDES;

EID: 84898970257     PISSN: 10742484     EISSN: 19404034     Source Type: Journal    
DOI: 10.1177/1074248413518968     Document Type: Article

References (27)

1. World Health Organization. Causes of Death in 2008. Global Health Observatory (GHO); May2011. http://www.who.int/gho/mortality-burden-disease/ causes-death-2008/en/index.html. Accessed September 10, 2013.
2. World Health Organization. Global health risks: mortality and burden of disease attributable to selected major risks; 2009. http://www.who.int/ healthinfo/global-burden-disease/GlobalHealthRisks-report-full.pdf. Accessed September 10, 2013.
3. World Health Organization. Raised cholesterol: situation and trends. Global Health Observatory (GHO). http://www.who.int/gho/ncd/risk-factors/ cholesterol-text/en/index.html. Accessed September 10, 2013.
4. Toth PP, Potter D, Ming EE. Prevalence of lipid abnormalities in the United States: the national health and nutrition examination survey 2003-2006. J Clin Lipidol. 2012 ; 6 (4). 325-330
5. Grundy SM. Small LDL, atherogenic dyslipidemia, and the metabolic syndrome. Circulation. 1997 ; 95 (1). 1-4
6. Kumar A, Singh V. Atherogenic dyslipidemia and diabetes mellitus: what's new in the management arena?. Vasc Health Risk Manag. 2010 ; 6: 665-669
7. Chehade JM, Gladysz M, Mooradian AD. Dyslipidemia in type 2 diabetes: prevalence, pathophysiology, and management. Drugs. 2013 ; 73 (4). 327-339
8. Fazio S. Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: a role for combination fibrate therapy. Clin Ther. 2008 ; 30 (2). 294-306
9. Ito MK, McKenney JM, Brinton EA. Maintaining cardiovascular health in patients with mixed dyslipidemia: optimizing the management of hypertriglyceridemia and non-HDL cholesterol. J Manag Care Pharm. 2009 ; 15 (1 supp S-c). S3 - S21
10. Aalbers J. ACCORD LIPID study results strengthen guideline approach of adding fenofibrate to therapy of dyslipidaemic type 2 diabetic patients. Cardiovasc J Afr. 2011 ; 21 (2). 118-119
11. McKeage K, Keating GM. Fenofibrate: a review of its use in dyslipidaemia. Drugs. 2011 ; 71 (14). 1917-1946
12. Tonkin AM, Chen L. Effects of combination lipid therapy in the management of patients with type 2 diabetes mellitus in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Circulation. 2010 ; 122 (8). 850-852
13. Liberopoulos EN, Florentin M, Mikhailidis DP, Elisaf MS. Compliance with lipid-lowering therapy and its impact on cardiovascular morbidity and mortality. Expert Opin Drug Saf. 2008 ; 7 (6). 717-725
14. Bates TR, Connaughton VM, Watts GF. Non-adherence to statin therapy: a major challenge for preventive cardiology. Expert Opin Pharmacother. 2009 ; 10 (18). 2973-2985
15. Perreault S, Dragomir A, Blais L, et al. Impact of better adherence to statin agents in the primary prevention of coronary artery disease. Eur J Clin Pharmacol. 2009 ; 65 (10). 1013-1024
16. Casula M, Tragni E, Catapano AL. Adherence to lipid-lowering treatment: the patient perspective. Patient Prefer Adherence. 2012 ; 6: 805-814
17. Mauskop A, Borden WB. Predictors of statin adherence. Curr Cardiol Rep. 2011 ; 13 (6). 553-558
18. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines. Circulation. 2004 ; 110 (2). 227-239
19. Thummel KE, Shen DD, Isoherranen N Goodman & Gilman's the Pharmacological Basis of Therapeutics. 12 th ed. New York: McGraw-Hill; 2011:1906, 1931. Brunton LL, ed. New York: McGraw-Hill ; 2011: 1906-1931.
20. Poli A. Atorvastatin: pharmacological characteristics and lipid-lowering effects. Drugs. 2007 ; 67 (suppl 1). 3-15
21. Athyros VG, Papageorgiou AA, Athyrou VV, Demitriadis DS, Kontopoulos AG. Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia. Diabetes Care. 2002 ; 25 (7). 1198-1202
22. Matalka MS, Ravnan MC, Deedwania PC. Is alternate daily dose of atorvastatin effective in treating patients with hyperlipidemia? The alternate day versus daily dosing of atorvastatin study (ADDAS). Am Heart J. 2002 ; 144 (4). 674-677
23. Keles T, Akar Bayram N, Kayhan T, et al. The comparison of the effects of standard 20 mg atorvastatin daily and 20 mg atorvastatin every other day on serum LDL-cholesterol and high sensitive C-reactive protein levels. Anadolu Kardiyol Derg. 2008 ; 8 (6). 407-412
24. Kayikcioglu M, Ozerkan F, Soydan I. Effectiveness and safety of alternate-day simvastatin and fenofibrate on mixed hyperlipidemia. Am J Cardiol. 1999 ; 83 (7). 1135-1137
25. Ong HT. Evidence-based prescribing of statins: a developing world perspective. PLoS Med. 2006 ; 3 (3). e50
26. Liao JK. Safety and efficacy of statins in Asians. Am J Cardiol. 2007 ; 99 (3). 410-414
27. Current Index of Medical Specialities (CIMS) India. Atorvastatin fenofibrate combination: price in India. http://www.cimsasia.com/India/drug/ search/atorvastatin%20%2B%20fenofibrate. Accessed September 13, 2013.